Jump to content

Benefits of Alimta Affirmed by Asian Study


Recommended Posts

LONDON (Thomson Financial) - Eli Lilly and Company said two new studies conducted in Asia have demonstrated the clinical benefit of its lung cancer drug Alimta.

The company said the data presented at the 12th World Conference on Lung Cancer provide further support of the efficacy of Alimta in treating non-small cell lung cancer, the world's most common form of cancer.

Alimta is currently indicated for the second-line treatment of non-small cell lung cancer in more than 85 countries.

In one study, a Japanese multicenter, randomised Phase II trial, pretreated patients with locally advanced or metastatic NSCLC demonstrated more than 12 months of median survival time when treated with Alimta.

'This is data showing that Alimta not only provides excellent outcomes but also a favourable quality of life in pretreated patients with non-small cell lung cancer,' said Dr Kaoru Kubota (nyse: KUB - news - people ) of the National Cancer Center Hospital East in Kashiwa, Japan and the study's principal investigator.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.